Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: StemRIM

Market Cap 17.8B 111M 95.61M 88.04M 82.67M 155M 10.49B 157M 1.04B 405M 5.14B 416M 408M P/E Ratio 2024
-13.6x
P/E Ratio 2025 -10.2x
Enterprise Value 10.81B 67.36M 58.05M 53.45M 50.19M 94.23M 6.37B 95.22M 632M 246M 3.12B 253M 247M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
47.55%
Yield 2024 *
-
Yield 2025 -
06-16 StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis CI
06-16 StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease MT
06-10 StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026 CI
05-12 Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide CI
04-15 StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study MT
04-15 StemRIM Inc. Announces Completion of Patient Enrollment in Phase 1/2 InvestigatorInitiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy CI
03-11 StemRIM Reports Earnings Results for the Half Year Ended January 31, 2026 CI
03-02 StemRIM Wins Patent for SR-GT1 Stem Cell Gene Therapy MT
03-02 StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology Aimed At Curative Treatment of Dystrophic Epidermolysis Bullosa CI
02-17 StemRIM Secures Canada Patent for Cartilage Disorder Use of Redasemtide MT
02-17 Stemrim Inc. Announces Patent Registration for the Use of Thehmgb1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders CI
12-24 Stemrim Inc. Announces Completion of Patient Enrollment in the Global Phase 2B Clinical Trial of the Redasemtide for Acute Ischemic Stroke CI
12-17 StemRIM Inc. Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis CI
1 day+5.63%
1 week+8.70%
Current month+1.35%
1 month+3.45%
3 months-1.32%
6 months+21.46%
Current year+14.07%
1 week 274
Extreme 274
304
1 month 273
Extreme 273
306
Current year 260
Extreme 260
326
1 year 246
Extreme 246
350
3 years 246
Extreme 246
1,100
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 65 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 65 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+5.63%+8.70%-13.54%-71.88% 111M
-0.04%-0.24%+17.61%-21.50% 62.54B
-1.00%-6.39%+56.50%+193.94% 55.22B
+0.08%+33.30%+33.30%+33.30% 40.9B
+0.51%+3.73%-55.37%-62.46% 35.99B
-1.53%-1.75%+49.28%-34.24% 28.88B
+6.27%+16.07%+113.08%-56.96% 21.98B
-2.19%-3.37%+40.06%+57.76% 19.93B
-2.03%+0.67%-2.92%+110.25% 16.95B
+0.63%-0.60%+54.10%+98.35% 15.87B
Average +0.09%+1.95%+29.21%+24.66% 29.84B
Weighted average by Cap. -0.44%+1.25%+30.51%+36.23%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.6M -10.86M -10M -9.39M -17.63M -1.19B -17.82M -118M -46.04M -583M -47.29M -46.29M -1.93B -12.02M -10.36M -9.54M -8.96M -16.82M -1.14B -17M -113M -43.92M -557M -45.12M -44.16M
Net Debt -8.41B -52.41M -45.17M -41.6M -39.05M -73.32M -4.96B -74.1M -492M -191M -2.43B -197M -193M -6.99B -43.59M -37.57M -34.59M -32.48M -60.98M -4.12B -61.62M -409M -159M -2.02B -164M -160M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Date Price Change Volume
26-06-17 300.00 ¥ +5.63% 295,100
26-06-16 284.00 ¥ -0.35% 48,900
26-06-15 285.00 ¥ -0.35% 73,800
26-06-12 286.00 ¥ +1.06% 156,700
26-06-11 283.00 ¥ +2.54% 173,700
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!